Seneca EIS portfolio company Redx Pharma has identified another potential blockbuster from its pipeline of drug candidates. Its oncology arm has found a would-be treatment for leukaemia and other blood cancers, and auto-immune diseases, such as lupus.
It is the second drug to come through the development system. Redx has 13 drug programmes in its pipeline.
Chief executive (CEO) Neil Murray said: “This drug candidate has the potential to demonstrate efficacy without the highly unpleasant side effects that many existing treatments display. We have a number of other promising candidates in the pipeline and we’re looking forward to seeing these progress into development in the near future.”
See the article in full at proactiveinvestors.co.uk
